ClearVue’s $3M Funding Deal Raises Dilution Questions Despite Non-Dilutive Claims
ClearVue Technologies has locked in a $3 million structured funding facility tied to its R&D tax credits, aiming to accelerate certification milestones and commercial deployment without diluting shareholders.
- A$3 million structured R&D funding facility secured from RiverFort
- Initial $1 million drawdown with $2 million available by agreement
- Non-dilutive bridge funding linked to FY26 R&D tax credit
- Funding to support certification, compliance, and commercial activities
- Attaching options exercisable at 130% of reference price included
Strategic Funding to Advance ClearVue’s Growth
ClearVue Technologies Limited (ASX:CPV) has taken a significant step to underpin its growth trajectory by securing a structured funding facility worth A$3 million from RiverFort Global Opportunities PCC Ltd. This bridge funding, secured against ClearVue’s FY26 Research & Development tax credit, is designed to provide the company with timely capital to progress critical certification milestones and commercialisation efforts.
The facility includes an initial advance of A$1 million, with a further A$2 million available subject to mutual agreement. This approach allows ClearVue to access necessary funds without immediate shareholder dilution, a move CEO Douglas Hunt emphasised as protecting and enhancing long-term shareholder value amid what the board views as current market undervaluation.
Non-Dilutive Capital with Strategic Flexibility
ClearVue’s choice of a structured R&D funding facility reflects a growing trend among technology companies to leverage government incentives while preserving equity. The funding is earmarked for advancing testing and certification programs, product compliance and validation, commercial deployment activities, and general working capital needs.
Importantly, the facility includes attaching options issued to RiverFort on each drawdown. These options are exercisable at 130% of the reference share price and expire after 24 months, introducing a potential future dilution factor but only if exercised. This structure aligns investor and company interests around ClearVue’s commercial success.
Partnering with RiverFort Amid Market Opportunities
RiverFort’s CEO Gytis Martinkus highlighted the strategic rationale behind the partnership, noting the clear addressable market growth driven by global decarbonisation efforts. ClearVue’s patented solar-integrated building materials position it well to capitalise on increasing demand for sustainable building solutions.
As a London-based specialist in structured finance, RiverFort’s involvement signals confidence in ClearVue’s technology and commercial pathway. Their funding model, aligned with R&D rebate cycles and milestone delivery, offers ClearVue a tailored capital solution during a critical phase of product validation and market expansion.
Looking Ahead
ClearVue’s latest funding announcement underscores its commitment to execution, completing compliance programs, supporting partner deployments, and converting commercial opportunities. While the facility provides a financial runway, the company’s ability to meet certification milestones and scale commercial deployments will be key to unlocking further value and justifying the market’s reassessment of its worth.
Bottom Line?
ClearVue’s structured funding deal offers a runway to prove its technology’s commercial viability while carefully balancing shareholder interests.
Questions in the middle?
- How quickly can ClearVue achieve its certification milestones with this funding?
- What commercial partnerships or deployments are expected to materialise in the near term?
- Will the attaching options lead to meaningful dilution if exercised, and when?
